Rifamycin antibiotics and the mechanisms of their failure

被引：41

作者：

Adams, Rebekah A. ^{[1
]}

Leon, Gabrielle ^{[1
]}

Miller, Natalia M. ^{[1
]}

Reyes, Saira P. ^{[1
]}

Thantrong, Chantal H. ^{[1
]}

Thokkadam, Alina M. ^{[1
]}

Lemma, Annabel S. ^{[1
]}

Sivaloganathan, Darshan M. ^{[2
]}

Wan, Xuanqing ^{[1
]}

Brynildsen, Mark P. ^{[1
,3
]}

机构：

[1] Princeton Univ, Dept Chem & Biol Engn, Princeton, NJ 08544 USA

[2] Princeton Univ, Program Quantitat & Computat Biol, Princeton, NJ 08544 USA

[3] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA

来源：

JOURNAL OF ANTIBIOTICS | 2021年 / 74卷 / 11期

关键词：

RESISTANT MYCOBACTERIUM-TUBERCULOSIS; MEDIATED RIFAMPIN RESISTANCE; BIOSYNTHETIC GENE-CLUSTER; RNA-POLYMERASE; IN-VITRO; RPOB GENE; STAPHYLOCOCCAL BIOFILMS; PULMONARY TUBERCULOSIS; COMBINATION THERAPY; INITIAL TREATMENT;

D O I：

10.1038/s41429-021-00462-x

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Rifamycins are a class of antibiotics that were first discovered in 1957 and are known for their use in treating tuberculosis (TB). Rifamycins exhibit bactericidal activity against many Gram-positive and Gram-negative bacteria by inhibiting RNA polymerase (RNAP); however, resistance is prevalent and the mechanisms range from primary target modification and antibiotic inactivation to cytoplasmic exclusion. Further, phenotypic resistance, in which only a subpopulation of bacteria grow in concentrations exceeding their minimum inhibitory concentration, and tolerance, which is characterized by reduced rates of bacterial cell death, have been identified as additional causes of rifamycin failure. Here we summarize current understanding and recent developments regarding this critical antibiotic class.

引用

页码：786 / 798

页数：13

共 138 条

[21] Forward Genetics Reveals agatC-gatAFusion Polypeptide Causes Mistranslation and Rifampicin Tolerance inMycobacterium smegmatis [J].

Cai, Rong-Jun ;

Su, Hong-Wei ;

Li, Yang-Yang ;

Javid, Babak .

FRONTIERS IN MICROBIOLOGY, 2020, 11

[22] EFFECT OF RIFAMYCIN ON PROTEIN SYNTHESIS [J].

CALVORI, C ;

FRONTALI, L ;

LEONI, L ;

TECCE, G .

NATURE, 1965, 207 (4995) :417-&

[23] Structural mechanism for rifampicin inhibition of bacterial RNA polymerase [J].

Campbell, EA ;

Korzheva, N ;

Mustaev, A ;

Murakami, K ;

Nair, S ;

Goldfarb, A ;

Darst, SA .

CELL, 2001, 104 (06) :901-912

[24]

CDC, 2019, TUB DAT STAT

[25] Plasmid-mediated rifampicin resistance in Pseudomonas fluorescens [J].

Chandrasekaran, S ;

Lalithakumari, D .

JOURNAL OF MEDICAL MICROBIOLOGY, 1998, 47 (03) :197-200

[26] Kasugamycin potentiates rifampicin and limits emergence of resistance in Mycobacterium tuberculosis by specifically decreasing mycobacterial mistranslation [J].

Chaudhuri, Swarnava ;

Li, Liping ;

Zimmerman, Matthew ;

Chen, Yuemeng ;

Chen, Yu-Xiang ;

Toosky, Melody N. ;

Gardner, Michelle ;

Pan, Miaomiao ;

Li, Yang-Yang ;

Kawaji, Qingwen ;

Zhu, Jun-Hao ;

Su, Hong-Wei ;

Martinot, Amanda J. ;

Rubin, Eric J. ;

Dartois, Veronique Anne ;

Javid, Babak .

ELIFE, 2018, 7

[27] RIFAMPIN IN INITIAL TREATMENT OF ADVANCED PULMONARY TUBERCULOSIS [J].

CORPE, RF ;

SANCHEZ, ES .

CHEST, 1972, 61 (06) :564-&

[28] RIBOSYLATION BY MYCOBACTERIAL STRAINS AS A NEW MECHANISM OF RIFAMPIN INACTIVATION [J].

DABBS, ER ;

YAZAWA, K ;

MIKAMI, Y ;

MIYAJI, M ;

MORISAKI, N ;

IWASAKI, S ;

FURIHATA, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (04) :1007-1009

[29] PROBABILITY DISTRIBUTION OF DRUG-RESISTANT MUTANTS IN UNSELECTED POPULATIONS OF MYCOBACTERIUM-TUBERCULOSIS [J].

DAVID, HL .

APPLIED MICROBIOLOGY, 1970, 20 (05) :810-&

[30] World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions [J].

Di Angelantonio, Emanuele ;

Kaptoge, Stephen ;

Pennells, Lisa ;

De Bacquer, Dirk ;

Cooney, Marie Therese ;

Kavousi, Maryam ;

Stevens, Gretchen ;

Riley, Leanne ;

Savin, Stefan ;

Altay, Servet ;

Amouyel, Philippe ;

Assmann, Gerd ;

Bell, Steven ;

Ben-Shlomo, Yoav ;

Berkman, Lisa ;

Beulens, Joline W. ;

Bjorkelund, Cecilia ;

Blaha, Michael J. ;

Blazer, Dan G. ;

Bolton, Thomas ;

Bonita, Ruth ;

Brenner, Beaglehole Hermann ;

Brunner, Eric J. ;

Casiglia, Edoardo ;

Chamnan, Parinya ;

Choi, Yeun-Hyang ;

Chowdhury, Rajiv ;

Coady, Sean ;

Crespo, Carlos J. ;

Cushman, Mary ;

Dagenais, Gilles R. ;

D'Agostino, Ralph B. ;

Daimon, Makoto ;

Davidson, Karina W. ;

Engstrom, Gunnar ;

Fang, Xianghua ;

Ford, Ian ;

Gallacher, John ;

Gansevoort, Ron T. ;

Gaziano, Thomas Andrew ;

Giampaoli, Simona ;

Grandits, Greg ;

Grimsgaard, Sameline ;

Grobbee, Diederick E. ;

Gudnason, Vilmundur ;

Guo, Qi ;

Humphries, Steve ;

Iso, Hiroyasu ;

Jukema, J. Wouter ;

Kauhanen, Jussi .

LANCET GLOBAL HEALTH, 2019, 7 (10) :E1332-E1345

← 1 2 3 4 5 6 7 8 9 10 →